Dupilumab with concomitant topical corticosteroids in adult patients with atopic dermatitis who are not adequately controlled with or are intolerant to ciclosporin A, or when this treatment is medically inadvisable: a placebo ‐controlled, randomized phase 3 clinical trial (LIBERTY AD CAFÉ)

ConclusionsDupilumab+TCS significantly improved signs and symptoms of AD and QOL in adults with history of inadequate response to/intolerance of CsA, or for whom CsA treatment was medically inadvisable. No new safety signals were identified.This article is protected by copyright. All rights reserved

Source: British Journal of Dermatology - October 1, 2017 Category: Dermatology Authors: M. de Bruin ‐Weller, D. Thaçi, C.H. Smith, K. Reich, M. Cork, A. Radin, Q. Zhang, B. Akinlade, A. Gadkari, L. Eckert, T. Hultsch, Z. Chen, G. Pirozzi, N.M.H. Graham, B. Shumel Tags: Original Article Source Type: research